RAPT

RAPT Therapeutics Inc

Add to Watchlist

Advanced Chart

13.310

+0.66(5.217%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

13.4589

Open

12.650

VWAP

12.97

Vol

66.31K

Mkt Cap

220.10M

Low

12.1412

Amount

860.37K

EV/EBITDA(TTM)

Total Shares

34.90M

29.91M

EV/OCF(TTM)

P/S(TTM)

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.780

-92.01%

-0.785

-79.13%

-0.644

-88.66%

Estimates Revision

The market is revising No Change the revenue expectations for RAPT Therapeutics, Inc. (RAPT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 89.36%.

EPS Estimates for FY2025

Revise Downward

-61.9%

In Past 3 Month

Stock Price

Go Up

+89.36%

In Past 3 Month

5 Analyst Rating

140.42% Upside

Wall Street analysts forecast RAPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPT is 32.00 USD with a low forecast of 8.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

1 Sell

Moderate Buy

140.42% Upside

Current: 13.310

Low

8.00

Averages

32.00

High

48.00

140.42% Upside

Current: 13.310

Low

8.00

Averages

32.00

High

48.00

LifeSci Capital

Outperform

initiated

$31

2025-07-22

New

Reason

LifeSci Capital

Price Target

$31

2025-07-22

New

initiated

Outperform

Reason

LifeSci Capital initiated coverage of Rapt Therapeutics with an Outperform rating and $31 price target.

LifeSci Capital

analyst

Outperform

initiated

$31

2025-07-22

New

Reason

LifeSci Capital

analyst

Price Target

$31

2025-07-22

New

initiated

Outperform

Reason

As previously reported, LifeSci Capital initiated coverage of Rapt Therapeutics with an Outperform rating and $31 price target. The initial developmental focus for lead asset RPT904 is on food allergy and chronic spontaneous urticaria, notes the analyst, who adds that both indications "represent large markets" in the U.S. These two indications amount to "a multi-billion-dollar opportunity," while Rapt also has two external catalysts in the form of Phase 2 readouts in asthma and CSU from their Chinese partner, Jemincare, the analyst added.

H.C. Wainwright

Emily Bodnar

Buy

upgrade

$6 -> $27

2025-07-10

Reason

H.C. Wainwright

Emily Bodnar

Price Target

$6 -> $27

2025-07-10

upgrade

Buy

Reason

H.C. Wainwright analyst Emily Bodnar raised the firm's price target on Rapt Therapeutics to $27 from $6 and keeps a Buy rating on the shares following the 1-for-8 reverse stock split.

Clear Street

NULL -> Buy

initiated

2025-06-05

Reason

Clear Street

Price Target

2025-06-05

initiated

NULL -> Buy

Reason

Clear Street initiated coverage of Rapt Therapeutics with a Buy rating and $3 price target.

Clear Street

Buy

initiated

2025-06-05

Reason

Clear Street

Price Target

2025-06-05

initiated

Buy

Reason

H.C. Wainwright

NULL -> Buy

initiated

2025-05-22

Reason

H.C. Wainwright

Price Target

2025-05-22

initiated

NULL -> Buy

Reason

H.C. Wainwright assumed coverage of Rapt Therapeutics with a Buy rating and $6 price target. The firm believes Rapt's primary candidate, RPT904, operates through a commercially validated mechanism targeting immunoglobulin E, significantly reducing target risk given omalizumab approval in multiple indications, including food allergy, asthma, and chronic spontaneous urticaria.

See All Ratings

Valuation Metrics

The current forward P/E ratio for RAPT Therapeutics Inc (RAPT.O) is -4.47, compared to its 5-year average forward P/E of -6.41. For a more detailed relative valuation and DCF analysis to assess RAPT Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.41

Current PE

-4.47

Overvalued PE

-2.87

Undervalued PE

-9.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.10

Current EV/EBITDA

-0.33

Overvalued EV/EBITDA

-0.63

Undervalued EV/EBITDA

-7.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

434.22

Current PS

0.00

Overvalued PS

1477.53

Undervalued PS

-609.09